Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.


Ailawadhi S., Špička I., Spencer A., Lu J., Oriol A., Ling S., ...More

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.43, no.27, pp.3056, 2025 (SCI-Expanded) identifier